查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128159

子宮內膜癌市場規模、佔有率、成長率、全球產業分析、區域趨勢及2026-2034年預測

Endometrial Cancer Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

子宮內膜癌市場成長要素

全球子宮內膜癌市場在2025年達到26.6億美元，預計2026年成長至30.1億美元，並在2034年達到79億美元，預測期內CAGR為12.84%。北美地區在全球市場中佔據領先地位，到2025年佔據46.61%的市場佔有率，這主要得益於其先進的醫療基礎設施、免疫療法的廣泛應用、生物標記檢測的普及以及有利的保險償付政策。

子宮內膜癌是全球女性最常見的婦科惡性腫瘤之一。該領域涵蓋早期、晚期、復發性和轉移性疾病的治療，治療策略正日益轉向精準醫療和基於免疫療法的聯合治療。製藥公司正積極投資研發、臨床試驗和法規核准，以改善患者預後並拓展治療選擇。該疾病日益成長的發病率，以及分子診斷技術的進步，持續為該行業創造強勁的成長機會。

免疫療法和精準醫療的廣泛應用推動市場成長。

隨著醫療機構擴大採用基於生物標記的療法進行個人化治療，市場正經歷重大變革。 PD-1抑制劑、標靶治療和聯合治療正成為進行性和復發性子宮內膜癌的首選治療方案。聯合治療免疫療法的核准範圍不斷擴大，使更多患者能夠獲得創新療法，加速了整體市場成長。

新型免疫腫瘤療法的不斷發展已成為一個重要的市場趨勢。

子宮內膜癌市場的關鍵趨勢之一是創新免疫腫瘤療法、抗體藥物複合體（ADC）和標靶治療的研發管線不斷擴展。製藥公司日益擴大其臨床開發計畫，以滿足復發性癌症或生物標記明確疾病患者的未滿足醫療需求。對 HER2 陽性、dMMR/MSI-H 和 pMMR 患者群體的日益關注，推動了癌症治療向個體化方向發展，並最終提高了患者的長期生存率。

市場促進因素

子宮內膜癌發生率的上升仍然是市場成長要素。老化、肥胖、糖尿病和代謝性疾病等因素導致全球診斷率不斷攀升。隨著越來越多的患者需要接受更先進的治療，醫院和癌症中心日益擴大分子檢測、免疫療法和分子標靶療法的應用範圍。持續的產品核准和適應症的擴大為醫生提供了更有效的治療選擇，進一步增強了市場需求。

市場限制因素

儘管科技快速發展，但先進療法的高成本仍限制了市場擴張。聯合治療、標靶治療、生物標記檢測和長期患者監測都會顯著增加治療成本。在開發中國家和對成本高度敏感的醫療體系中，即使臨床療效已得到證實，保險償付的限制也常常會延緩昂貴療法的引進，並限制患者的就醫途徑。

市場機會

基於生物標記的治療策略的拓展為市場參與企業帶來了巨大的成長機會。精準醫療使醫生能夠根據分子特徵選擇治療方案，提高治療反應率和患者存活率。製藥公司正日益開發針對HER2表達陽性、MSI-H、dMMR和pMMR患者群體的標靶治療，不僅支持了個人化癌症治療，也創造了新的商業性機會。

細分分析

依藥物類別分類，PD-1抑制劑2025年佔據市場主導地位，並在進行性和復發性子宮內膜癌中展現臨床療效。廣泛的核准適應症、優異的生存率以及與化療聯合應用的日益普及，進一步推動了該細分市場的成長。預計PD-L1抑制劑細分市場在預測期內將實現最快成長。

就癌症類型而言，子宮內膜樣腺癌佔全球確診子宮癌病例的絕大多數，因此佔據最大的市場佔有率。其主導地位得益於龐大的患者群體以及手術、化療、免疫療法和荷爾蒙療法的廣泛應用。

就治療方法而言，化療在2025年仍將佔據主要治療領域。這是含鉑類藥物和紫杉烷類為基礎的化療方案仍將作為第一線標準治療的基礎。然而，由於核准藥物的增加和醫生接受度的提高，預計免疫療法將呈現最高的成長速度。

由於化療和免疫療法治療需要專家的監督，並且是在醫院進行的，因此醫院藥房在通路領域佔據了主導地位。

區域展望

北美引領全球子宮內膜癌市場，到2025年市場規模達12.4億美元。該地區受益於許多因素，例如完善的癌症醫療基礎設施、高診斷率、廣泛的生物標記檢測以及創新免疫療法的快速普及。美國仍然是該地區最大的銷售額貢獻者。

歐洲是第二大區域市場，這得益於法規核准的擴大、國家癌症計畫的推進以及基於免疫療法的聯合療法的日益普及。德國和英國透過改善先進癌症治療的可近性，持續推動區域市場的成長。

由於患者數量增加、醫療基礎設施改善、癌症防治意識提高以及先進腫瘤治療手段的普及，亞太地區預計將迎來顯著成長。中國、日本和印度預計在整個預測期內仍將是關鍵的成長市場。

在拉丁美洲、中東和非洲地區，隨著醫療保健投資的增加、癌症診斷技術的改進以及新興經濟體獲得先進治療的機會逐步擴大，預計將實現穩步成長。

2026年4月，BioNTech宣布其trastuzumab pamirtecan治療HER2表達進行性子宮內膜癌的II期臨床試驗取得正面結果。同月，Utepreva LLC推出了一款獲得FDA已通過核准的子宮內膜取樣裝置，目的是提高早期診斷率。2024年8月，GSK 獲得美國 FDA 批准，將 Jemperli與carboplatin及paclitaxel聯合用於治療進行性或復發性子宮內膜癌，進一步拓展了免疫療法的治療選擇。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢
  • 市場挑戰

第4章 主要考察

  • 2025年各國/地區子宮內膜癌盛行率
  • 新產品發布：依主要公司分類
  • 主要地區和國家的監管情況概述
  • 主要產業趨勢（合併、收購、合作等）
  • 管道分析：依主要公司分類

第5章 2021-2034年全球子宮內膜癌市場分析、洞察與預測

  • 市場分析、洞察與預測：依藥物類別分類
    • PD-1抑制劑
    • 鉑化合物
    • 紫杉烷類藥物
    • VEGFR/多激酶抑制劑
    • 黃體素
    • PD-L1抑制劑
    • 其他
  • 市場分析、洞察與預測：依癌症類型分類
    • 子宮內膜樣腺癌
    • 漿液性子宮內膜癌
    • 透明細胞癌
    • 癌症肉瘤
    • 其他
  • 市場分析、洞察與預測：依年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：依療法分類
    • 化療
    • 免疫療法
    • 標靶治療
    • 荷爾蒙療法
    • 其他
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 腸外
  • 市場分析、洞察與預測：依通路分類
    • 醫院藥房
    • 藥局和零售藥房
    • 網路藥房
    • 專科藥房
  • 分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美子宮內膜癌市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲子宮內膜癌市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區子宮內膜癌市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章 2021-2034年中東和非洲子宮內膜癌市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第10章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Merck & Co., Inc.
    • Eisai Co., Ltd.
    • GSK plc
    • AstraZeneca PLC
    • Pfizer Inc.
    • Fresenius Kabi AG
    • Hikma Pharmaceuticals PLC
    • Teva Pharmaceutical Industries Ltd.
    • Accord Healthcare Limited
    • Bristol Myers Squibb Company
Product Code: FBI117372

Growth Factors of endometrial cancer Market

The global endometrial cancer market was valued at USD 2.66 billion in 2025 and is projected to grow from USD 3.01 billion in 2026 to USD 7.90 billion by 2034, registering a CAGR of 12.84% during the forecast period. North America dominated the global market with a 46.61% market share in 2025, supported by advanced healthcare infrastructure, increasing adoption of immunotherapy, widespread biomarker testing, and favorable reimbursement policies.

Endometrial cancer is one of the most common gynecologic malignancies affecting women worldwide. The market includes therapies for early-stage, advanced, recurrent, and metastatic disease, with treatment strategies increasingly shifting toward precision medicine and immunotherapy-based combinations. Pharmaceutical companies are actively investing in research and development, clinical trials, and regulatory approvals to improve patient outcomes and expand treatment options. The growing incidence of the disease, coupled with advancements in molecular diagnostics, continues to create strong growth opportunities for the industry.

Growing Adoption of Immunotherapy and Precision Medicine Drives Market Growth

The market is experiencing significant transformation as healthcare providers increasingly adopt biomarker-guided therapies for personalized treatment. PD-1 inhibitors, targeted therapies, and combination regimens are becoming the preferred treatment options for advanced and recurrent endometrial cancer. Expanded regulatory approvals for immunotherapy combinations are enabling more patients to access innovative treatments, thereby accelerating overall market growth.

Rising Development of Novel Immuno-Oncology Therapies Emerges as a Key Market Trend

One of the major trends shaping the endometrial cancer market is the growing pipeline of innovative immuno-oncology therapies, antibody-drug conjugates, and targeted medicines. Pharmaceutical companies are expanding clinical development programs to address unmet needs among patients with recurrent or biomarker-defined disease. The increasing focus on HER2-positive, dMMR/MSI-H, and pMMR patient populations is supporting the transition toward personalized cancer care and improving long-term survival outcomes.

Market Drivers

The rising incidence of endometrial cancer remains the primary growth driver for the market. Factors such as aging populations, obesity, diabetes, and metabolic disorders are contributing to increasing diagnosis rates worldwide. As more patients require advanced treatment, hospitals and oncology centers are expanding access to molecular testing, immunotherapy, and targeted medicines. Continuous product approvals and label expansions further strengthen market demand by providing physicians with more effective treatment options.

Market Restraints

Despite rapid innovation, the high cost of advanced therapies continues to limit market expansion. Immunotherapy combinations, targeted drugs, biomarker testing, and long-term patient monitoring significantly increase treatment expenses. In developing countries and cost-sensitive healthcare systems, reimbursement limitations often delay the adoption of premium therapies, restricting patient access despite demonstrated clinical benefits.

Market Opportunities

The expansion of biomarker-guided treatment strategies presents significant growth opportunities for market participants. Precision medicine enables physicians to select therapies based on molecular characteristics, improving treatment response and patient survival. Pharmaceutical companies are increasingly developing targeted therapies for HER2-expressing, MSI-H, dMMR, and pMMR patient populations, creating new commercial opportunities while supporting personalized oncology care.

Segmentation Analysis

Based on drug class, PD-1 inhibitors dominated the market in 2025 due to their proven clinical effectiveness in advanced and recurrent endometrial cancer. Their broad regulatory approvals, strong survival outcomes, and increasing use alongside chemotherapy continue to strengthen segment growth. The PD-L1 inhibitors segment is expected to witness the fastest expansion during the forecast period.

By cancer type, endometrioid adenocarcinoma accounted for the largest market share because it represents the majority of diagnosed endometrial cancer cases worldwide. The large patient population and broad use of surgery, chemotherapy, immunotherapy, and hormonal therapy support its leading position.

Based on therapy, chemotherapy remained the dominant treatment segment in 2025, as platinum-taxane regimens continue to serve as the standard first-line treatment backbone, even when combined with immunotherapy. However, immunotherapy is expected to register the highest growth due to increasing approvals and wider physician acceptance.

Hospital pharmacies dominated the distribution channel segment owing to the hospital-based administration of chemotherapy and immunotherapy treatments requiring specialist supervision.

Regional Outlook

North America led the global endometrial cancer market with a valuation of USD 1.24 billion in 2025. The region benefits from strong oncology infrastructure, high diagnosis rates, widespread biomarker testing, and rapid adoption of innovative immunotherapies. The U.S. remains the largest contributor to regional revenue.

Europe represents the second-largest regional market, supported by expanding regulatory approvals, national cancer programs, and increasing use of immunotherapy-based treatment combinations. Germany and the U.K. continue to drive regional growth through improved access to advanced oncology care.

Asia Pacific is projected to experience substantial growth due to its expanding patient population, improving healthcare infrastructure, increasing cancer awareness, and rising availability of modern oncology treatments. China, Japan, and India are expected to remain key growth markets throughout the forecast period.

Latin America and the Middle East & Africa are anticipated to record steady growth as healthcare investments increase, cancer diagnosis improves, and access to advanced therapies gradually expands across emerging economies.

Competitive Landscape

The global endometrial cancer market is moderately consolidated, with major companies investing heavily in research, biomarker-based drug development, regulatory approvals, and strategic collaborations. Leading companies include Merck & Co., Inc., Eisai Co., Ltd., GSK plc, AstraZeneca PLC, Pfizer Inc., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Accord Healthcare Limited, and Bristol Myers Squibb Company. Ongoing clinical trials, product launches, and label expansions continue to strengthen competition across the market.

Recent Industry Developments

In April 2026, BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing advanced endometrial cancer. During the same month, Utepreva LLC launched an FDA-cleared endometrial sampling device designed to improve early diagnosis. In August 2024, GSK received U.S. FDA approval for Jemperli combined with carboplatin and paclitaxel for advanced or recurrent endometrial cancer, further expanding immunotherapy treatment options.

Conclusion

The global endometrial cancer market is expected to witness strong growth through 2034, driven by rising disease incidence, increasing adoption of precision medicine, expanding biomarker testing, and continuous innovation in immunotherapy and targeted therapies. With growing investments in research and development, favorable regulatory approvals, and broader access to personalized treatment approaches, the market is well-positioned for sustained expansion between 2026 and 2034.

Segmentation By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Region

By Drug Class * PD-1 Inhibitors

  • Platinum Compounds
  • Taxanes
  • VEGFR/Multikinase Inhibitors
  • Progestins
  • PD-L1 Inhibitors
  • Others

By Cancer Type * Endometrioid Adenocarcinoma

  • Serous Endometrial Carcinoma
  • Clear Cell Carcinoma
  • Carcinosarcoma
  • Others

By Age Group * Pediatric

  • Adults

By Therapy * Chemotherapy

  • Immunotherapy
  • Targeted Therapy
  • Hormonal Therapy
  • Others

By Route of Administration * Oral

  • Parenteral

By Distribution Channel * Hospital Pharmacies

  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies

By Region * North America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Cancer Type, Age Group, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends
  • 3.5. Market Challenges

4. Key Insights

  • 4.1. Prevalence of Endometrial Cancer, By Countries/Region, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Overview of Regulatory Scenario, By Key Regions/ Countries
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Pipeline Analysis, By Key Players

5. Global Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. PD-1 Inhibitors
    • 5.1.2. Platinum Compounds
    • 5.1.3. Taxanes
    • 5.1.4. VEGFR/Multikinase Inhibitors
    • 5.1.5. Progestins
    • 5.1.6. PD-L1 Inhibitors
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.2.1. Endometrioid Adenocarcinoma
    • 5.2.2. Serous Endometrial Carcinoma
    • 5.2.3. Clear Cell Carcinoma
    • 5.2.4. Carcinosarcoma
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Therapy
    • 5.4.1. Chemotherapy
    • 5.4.2. Immunotherapy
    • 5.4.3. Targeted Therapy
    • 5.4.4. Hormonal Therapy
    • 5.4.5. Others
  • 5.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.5.1. Oral
    • 5.5.2. Parenteral
  • 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Drug Stores & Retail Pharmacies
    • 5.6.3. Online Pharmacies
    • 5.6.4. Specialty Pharmacies
  • 5.7. Market Analysis, Insights and Forecast - Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. PD-1 Inhibitors
    • 6.1.2. Platinum Compounds
    • 6.1.3. Taxanes
    • 6.1.4. VEGFR/Multikinase Inhibitors
    • 6.1.5. Progestins
    • 6.1.6. PD-L1 Inhibitors
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 6.2.1. Endometrioid Adenocarcinoma
    • 6.2.2. Serous Endometrial Carcinoma
    • 6.2.3. Clear Cell Carcinoma
    • 6.2.4. Carcinosarcoma
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Therapy
    • 6.4.1. Chemotherapy
    • 6.4.2. Immunotherapy
    • 6.4.3. Targeted Therapy
    • 6.4.4. Hormonal Therapy
    • 6.4.5. Others
  • 6.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.5.1. Oral
    • 6.5.2. Parenteral
  • 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Drug Stores & Retail Pharmacies
    • 6.6.3. Online Pharmacies
    • 6.6.4. Specialty Pharmacies
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. PD-1 Inhibitors
    • 7.1.2. Platinum Compounds
    • 7.1.3. Taxanes
    • 7.1.4. VEGFR/Multikinase Inhibitors
    • 7.1.5. Progestins
    • 7.1.6. PD-L1 Inhibitors
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 7.2.1. Endometrioid Adenocarcinoma
    • 7.2.2. Serous Endometrial Carcinoma
    • 7.2.3. Clear Cell Carcinoma
    • 7.2.4. Carcinosarcoma
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Therapy
    • 7.4.1. Chemotherapy
    • 7.4.2. Immunotherapy
    • 7.4.3. Targeted Therapy
    • 7.4.4. Hormonal Therapy
    • 7.4.5. Others
  • 7.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.5.1. Oral
    • 7.5.2. Parenteral
  • 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Drug Stores & Retail Pharmacies
    • 7.6.3. Online Pharmacies
    • 7.6.4. Specialty Pharmacies
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Italy
    • 7.7.5. Spain
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. PD-1 Inhibitors
    • 8.1.2. Platinum Compounds
    • 8.1.3. Taxanes
    • 8.1.4. VEGFR/Multikinase Inhibitors
    • 8.1.5. Progestins
    • 8.1.6. PD-L1 Inhibitors
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.2.1. Endometrioid Adenocarcinoma
    • 8.2.2. Serous Endometrial Carcinoma
    • 8.2.3. Clear Cell Carcinoma
    • 8.2.4. Carcinosarcoma
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Therapy
    • 8.4.1. Chemotherapy
    • 8.4.2. Immunotherapy
    • 8.4.3. Targeted Therapy
    • 8.4.4. Hormonal Therapy
    • 8.4.5. Others
  • 8.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.5.1. Oral
    • 8.5.2. Parenteral
  • 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Drug Stores & Retail Pharmacies
    • 8.6.3. Online Pharmacies
    • 8.6.4. Specialty Pharmacies
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.7.1. China
    • 8.7.2. Japan
    • 8.7.3. India
    • 8.7.4. Southeast Asia
    • 8.7.5. Australia
    • 8.7.6. Rest of Asia Pacific
  • 8.8. Market Analysis, Insights and Forecast - By Drug Class
    • 8.8.1. PD-1 Inhibitors
    • 8.8.2. Platinum Compounds
    • 8.8.3. Taxanes
    • 8.8.4. VEGFR/Multikinase Inhibitors
    • 8.8.5. Progestins
    • 8.8.6. PD-L1 Inhibitors
    • 8.8.7. Others
  • 8.9. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.9.1. Endometrioid Adenocarcinoma
    • 8.9.2. Serous Endometrial Carcinoma
    • 8.9.3. Clear Cell Carcinoma
    • 8.9.4. Carcinosarcoma
    • 8.9.5. Others
  • 8.10. Market Analysis, Insights and Forecast - By Age Group
    • 8.10.1. Pediatric
    • 8.10.2. Adults
  • 8.11. Market Analysis, Insights and Forecast - By Therapy
    • 8.11.1. Chemotherapy
    • 8.11.2. Immunotherapy
    • 8.11.3. Targeted Therapy
    • 8.11.4. Hormonal Therapy
    • 8.11.5. Others
  • 8.12. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.12.1. Oral
    • 8.12.2. Parenteral
  • 8.13. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.13.1. Hospital Pharmacies
    • 8.13.2. Drug Stores & Retail Pharmacies
    • 8.13.3. Online Pharmacies
    • 8.13.4. Specialty Pharmacies
  • 8.14. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.14.1. Brazil
    • 8.14.2. Mexico
    • 8.14.3. Rest of Latin America

9. Middle East & Africa Endometrial Cancer Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. PD-1 Inhibitors
    • 9.1.2. Platinum Compounds
    • 9.1.3. Taxanes
    • 9.1.4. VEGFR/Multikinase Inhibitors
    • 9.1.5. Progestins
    • 9.1.6. PD-L1 Inhibitors
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Cancer Type
    • 9.2.1. Endometrioid Adenocarcinoma
    • 9.2.2. Serous Endometrial Carcinoma
    • 9.2.3. Clear Cell Carcinoma
    • 9.2.4. Carcinosarcoma
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Therapy
    • 9.4.1. Chemotherapy
    • 9.4.2. Immunotherapy
    • 9.4.3. Targeted Therapy
    • 9.4.4. Hormonal Therapy
    • 9.4.5. Others
  • 9.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.5.1. Oral
    • 9.5.2. Parenteral
  • 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Drug Stores & Retail Pharmacies
    • 9.6.3. Online Pharmacies
    • 9.6.4. Specialty Pharmacies
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.7.1. GCC
    • 9.7.2. South Africa
    • 9.7.3. Rest of Middle East & Africa

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Merck & Co., Inc.
    • 10.2.2. Eisai Co., Ltd.
    • 10.2.3. GSK plc
    • 10.2.4. AstraZeneca PLC
    • 10.2.5. Pfizer Inc.
    • 10.2.6. Fresenius Kabi AG
    • 10.2.7. Hikma Pharmaceuticals PLC
    • 10.2.8. Teva Pharmaceutical Industries Ltd.
    • 10.2.9. Accord Healthcare Limited
    • 10.2.10. Bristol Myers Squibb Company

List of Tables

  • Table 1: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 3: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 4: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 5: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 6: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 7: Global Endometrial Cancer Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 9: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 10: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 11: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 12: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 14: North America Endometrial Cancer Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 15: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 16: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 17: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 18: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 19: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 20: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 21: Europe Endometrial Cancer Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 24: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 25: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 26: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 28: Asia Pacific Endometrial Cancer Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 29: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 30: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 31: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 32: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 33: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 34: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 35: Latin America Endometrial Cancer Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 37: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 38: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 39: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 40: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 41: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Endometrial Cancer Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Endometrial Cancer Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Endometrial Cancer Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Endometrial Cancer Market Value Share (%), by Cancer Type, 2025 & 2034
  • Figure 4: Global Endometrial Cancer Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Endometrial Cancer Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 6: Global Endometrial Cancer Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 7: Global Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 8: Global Endometrial Cancer Market Value Share (%), by Region, 2025 & 2034
  • Figure 9: North America Endometrial Cancer Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 10: North America Endometrial Cancer Market Value Share (%), by Drug Class, 2025
  • Figure 11: North America Endometrial Cancer Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 12: North America Endometrial Cancer Market Value Share (%), by Cancer Type, 2025
  • Figure 13: North America Endometrial Cancer Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 14: North America Endometrial Cancer Market Value Share (%), by Age Group 2025
  • Figure 15: North America Endometrial Cancer Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 16: North America Endometrial Cancer Market Value Share (%), by Therapy, 2025
  • Figure 17: North America Endometrial Cancer Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 18: North America Endometrial Cancer Market Value Share (%), by Route of Administration, 2025
  • Figure 19: North America Endometrial Cancer Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Endometrial Cancer Market Value (USD billion), by Country, 2025 & 2034
  • Figure 22: North America Endometrial Cancer Market Value Share (%), by Country, 2025
  • Figure 23: Europe Endometrial Cancer Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 24: Europe Endometrial Cancer Market Value Share (%), by Drug Class, 2025
  • Figure 25: Europe Endometrial Cancer Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 26: Europe Endometrial Cancer Market Value Share (%), by Cancer Type, 2025
  • Figure 27: Europe Endometrial Cancer Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 28: Europe Endometrial Cancer Market Value Share (%), by Age Group 2025
  • Figure 29: Europe Endometrial Cancer Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 30: Europe Endometrial Cancer Market Value Share (%), by Therapy, 2025
  • Figure 31: Europe Endometrial Cancer Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Europe Endometrial Cancer Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Europe Endometrial Cancer Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Europe Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Europe Endometrial Cancer Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe Endometrial Cancer Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Endometrial Cancer Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Asia Pacific Endometrial Cancer Market Value Share (%), by Drug Class, 2025
  • Figure 39: Asia Pacific Endometrial Cancer Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 40: Asia Pacific Endometrial Cancer Market Value Share (%), by Cancer Type, 2025
  • Figure 41: Asia Pacific Endometrial Cancer Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 42: Asia Pacific Endometrial Cancer Market Value Share (%), by Age Group 2025
  • Figure 43: Asia Pacific Endometrial Cancer Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 44: Asia Pacific Endometrial Cancer Market Value Share (%), by Therapy, 2025
  • Figure 45: Asia Pacific Endometrial Cancer Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 46: Asia Pacific Endometrial Cancer Market Value Share (%), by Route of Administration, 2025
  • Figure 47: Asia Pacific Endometrial Cancer Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 48: Asia Pacific Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025
  • Figure 49: Asia Pacific Endometrial Cancer Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific Endometrial Cancer Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 51: Latin America Endometrial Cancer Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 52: Latin America Endometrial Cancer Market Value Share (%), by Drug Class, 2025
  • Figure 53: Latin America Endometrial Cancer Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 54: Latin America Endometrial Cancer Market Value Share (%), by Cancer Type, 2025
  • Figure 55: Latin America Endometrial Cancer Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 56: Latin America Endometrial Cancer Market Value Share (%), by Age Group 2025
  • Figure 57: Latin America Endometrial Cancer Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 58: Latin America Endometrial Cancer Market Value Share (%), by Therapy, 2025
  • Figure 59: Latin America Endometrial Cancer Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 60: Latin America Endometrial Cancer Market Value Share (%), by Route of Administration, 2025
  • Figure 61: Latin America Endometrial Cancer Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 62: Latin America Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025
  • Figure 63: Latin America Endometrial Cancer Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America Endometrial Cancer Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 66: Middle East & Africa Endometrial Cancer Market Value Share (%), by Drug Class, 2025
  • Figure 67: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 68: Middle East & Africa Endometrial Cancer Market Value Share (%), by Cancer Type, 2025
  • Figure 69: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Age Group 2025 & 2034
  • Figure 70: Middle East & Africa Endometrial Cancer Market Value Share (%), by Age Group 2025
  • Figure 71: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 72: Middle East & Africa Endometrial Cancer Market Value Share (%), by Therapy, 2025
  • Figure 73: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 74: Middle East & Africa Endometrial Cancer Market Value Share (%), by Route of Administration, 2025
  • Figure 75: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 76: Middle East & Africa Endometrial Cancer Market Value Share (%), by Distribution Channel, 2025
  • Figure 77: Middle East & Africa Endometrial Cancer Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa Endometrial Cancer Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 79: Global Endometrial Cancer Market Share (%), by Company, 2025